Skip to main content
Top
Published in:

01-06-2025 | Alzheimer Disease | Review

Novel strategies for targeting tau oligomers in neurodegenerative diseases

Authors: Jing Lin, Hong Li, Lingxia Jiang, Jian Li

Published in: Journal of Neurology | Issue 6/2025

Login to get access

Abstract

Tau protein is a soluble microtubule-associated protein enriched in neurons, is mainly distributed in the central nervous system, and is responsible for stabilizing neurons. Tau maintains nerve cell morphology and internal transport by binding to normal microtubules. In neurodegenerative diseases, such as Alzheimer's disease (AD), tau proteins undergo aberrant phosphorylation, resulting in their removal from microtubules and the formation of neurofibrillary tangles (NFTs), which are key pathological features. In contrast to the late formation of non-soluble NFTs, early, smaller, soluble tau oligomers (tauO) with disseminated toxicity are considered necessary in neurodegenerative disorders, such as the primary form of tau toxicity in the AD process. Although an increasing number of studies are focusing on tauO, there are still problems to be solved, mainly concerning the molecular and inhibitory mechanisms of tauO toxicity. In this paper, we summarize the new strategies for the molecular mechanisms of tauO toxicity, detection methods, and interventions in the last five years. An outlook on these new strategies and the challenges that may be foreseen is presented to provide new directions for future applications in the clinical treatment of neurodegenerative diseases.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Novel strategies for targeting tau oligomers in neurodegenerative diseases
Authors
Jing Lin
Hong Li
Lingxia Jiang
Jian Li
Publication date
01-06-2025
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 6/2025
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-025-13117-w

EAN 2025

Unlock your free and exclusive access to the latest news and expert interviews from the European Academy of Neurology's annual congress.

Read more

How can your team use biomarkers to improve management of AD? (Link opens in a new window)

Our experts explore using biomarker tests and interpreting results, establishing a shared decision-making approach with patients and caregivers, and applying biomarker testing to guide treatment strategies.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Health+ IME
Register your interest